Elagolix compared with birth control pills for endometriosis pelvic pain
Compares elagolix and birth control pills for pelvic pain from endometriosis.
Key facts
- Who runs it
- Pak Emirates Military Hospital
- Where
- Rawalpindi, PakistanSee the site
- Trial code
- Registry title
- Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain
- Status
- Enrolling by invitation
- Phase
- Phase 4
- People taking part
- 90 people, planned
- Started
- 1 May 2026
- Planned end
- 1 Nov 2026
- Type of study
- Interventional, 2 groups
- Treatments tested
- Elagolix
- Oral Contraceptive (OC)
- Record updated
- 16 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with endometriosis who have regular periods, to compare two treatments for pelvic pain.
- Age
- 18 to 45 years
- Sex
- Women only
- Disease stage
- Endometriosis confirmed by a doctor's examination or by surgery
Main reasons for not taking part
- Reasons the pill (OCPs) is unsafe, such as blood clots, heart disease, uncontrolled high blood pressure, or smoking over age 35
- Reasons Elagolix is unsafe, such as osteoporosis, pregnancy, allergy to it, or severe depression
- Earlier removal of the womb or of both ovaries
- Another identifiable cause of pelvic pain
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Women aged 18-45 years
- clinically or surgically confirmed endometriosis
- having regular menstrual cycles
- willingness to participate with informed consent
Who cannot take part
- Contraindications to Elagolix (e.g., osteoporosis, pregnancy, hypersensitivity, severe depression) Prior hysterectomy or bilateral oophorectomy, Other identifiable causes of pelvic pain
- Contraindications to OCPs (e.g., thromboembolism, cardiovascular disease, uncontrolled hypertension, smoking over age 35)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Where in Pakistan
- Pak Emirates Military HospitalRawalpindi, PakistanNo longer taking part
About the trial
What the trial wants to find out
This study is designed to provide direct evidence on the relative effectiveness and safety of Elagolix versus OCPs, helping physicians make more tailored treatment decisions.
The 2 groups in the trial
- Elagolix GroupTreatment being tested
45 participants in Elagolix group. Elagolix will be administered at 150 mg once daily in this study.
Treatment: Elagolix
- OCPs groupTreatment being tested
45 Participants in this group. OCPs will be administered once daily in a continuous 28-day cycles for 3 months.
Treatment: Oral Contraceptive (OC)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Comparison of Efficacy and Safety of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic Pain
- Plain-language title
- Elagolix compared with birth control pills for endometriosis pelvic painGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Fit questions
- Built from NCT07532876, who can take part
- Record updated
- 16 April 2026